Northeast Financial Consultants Inc Clearside Biomedical, Inc. Transaction History
Northeast Financial Consultants Inc
- $2.25 Billion
- Q3 2024
A detailed history of Northeast Financial Consultants Inc transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Northeast Financial Consultants Inc holds 93,000 shares of CLSD stock, worth $80,910. This represents 0.01% of its overall portfolio holdings.
Number of Shares
93,000
Previous 93,000
-0.0%
Holding current value
$80,910
Previous $120,000
1.67%
% of portfolio
0.01%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding CLSD
# of Institutions
55Shares Held
12.2MCall Options Held
54.7KPut Options Held
50.7K-
Vanguard Group Inc Valley Forge, PA2.84MShares$2.47 Million0.0% of portfolio
-
Act Capital Management, LLC Wayne, PA2.2MShares$1.91 Million3.43% of portfolio
-
Carmignac Gestion Paris, I01.93MShares$1.68 Million0.04% of portfolio
-
Black Rock Inc. New York, NY798KShares$694,3790.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny745KShares$648,0530.0% of portfolio
About Clearside Biomedical, Inc.
- Ticker CLSD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,190,700
- Market Cap $52.4M
- Description
- Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...